Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Appoints CEO Michel Spagnol as Chairman

Published: Wednesday, March 05, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
Novasep presents strategic developments.

Novasep has announced the appointment of Michel Spagnol as chairman of the Supervisory Board, following the departure of Roger-Marc Nicoud, the founder of the group. Novasep also provides an update of its strategic projects.

Michel Spagnol joined Novasep as its CEO in June 2013. Since then, he has reinforced the executive management team with the appointments of Christian Thiry as chief financial officer, Thierry Van Nieuwenhove as president of the Synthesis Business Unit and the promotion of Nadege Laborde as president of the Industrial Biotech Unit.

Michel Spagnol also engaged the company in a number of strategic orientations, encompassing commercial, operational, human and innovation excellence, aimed at focusing on customer satisfaction.

Novasep has achieved significant milestones for its key development projects, such as the completion of the world’s largest chromatographic plant for the purification of omega-3s at its Mourenx facility, France, and the successful validation of its ADC payload commercial production workshops at its Le Mans facility, France.

In the last nine months, these facilities and the Leverkusen site in Germany received successful FDA inspections, demonstrating Novasep’s continued commitment to quality.

“Since October 2012, as chairman of Novasep’s Supervisory Board, I have assisted the executive management team in order to ensure that my succession proceeds in the best possible conditions,” said Roger-Marc Nicoud. “Novasep achieved satisfying growth in 2013. The company has promising projects underway and the necessary human and financial resources to achieve them. With the arrival of Michel Spagnol as CEO, I consider my support work to be completed. I have decided to devote myself entirely to other technical and scientific activities. I wish Michel all the best in his new role of CEO and chairman of the Supervisory Board and great success to all Novasep employees.”

“I thank Roger Marc for his never-ending enthusiasm and contribution to the group’s development and I have profound respect for what he has achieved,” said Michel Spagnol, CEO and chairman of the Supervisory Board. “A unique entrepreneur, he succeeded in building from scratch a global leader in the life science manufacturing industry, recognized worldwide for its unique technologies and capabilities. Novasep is evolving, with a strong leadership team and a new logo ‘Passion and smart processes’, representing our refocused strategy. We will continue building on our strong foundations while developing on the excellence of our services and technologies. I wish Roger-Marc continued success in his new endeavors.”

“We would like to thank Roger-Marc who, over the last year and a half, has contributed his unprecedented experience and scientific expertise as chairman of Novasep’s Supervisory Board. We wish him all the best for his new endeavors,” said Jean-Yves Gilet, director - Bpifrance ETI/GE.

Gilet continued, “We are confident about Novasep’s recent developments. The company is implementing promising projects such as the ADC payload production capacities in the Le Mans facility and the chromatographic plant for the purification of omega-3s in Mourenx. We fully support its strong management team led by Michel Spagnol who we are happy to see appointed as chairman of the Supervisory Board.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Pushes Further into Japanese Biopharma Market
Stronger local representation in growing Japanese biopharma market will improve Novasep’s capacity to equip and service Japanese clients.
Friday, November 18, 2016
Novasep, Triclinic Labs Partner
Partnership will enable Novasep to offer early-stage solid-state chemistry services in North America.
Thursday, September 15, 2016
Novasep Appoints Dr. François D’Hooge as Bioconjugation Unit Manager
Dr. D’Hooge will manage Novasep’s new antibody drug conjugates (ADC) production facility in Le Mans, France, currently undergoing completion.
Tuesday, September 06, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Appoints Fine Chemicals Market Director
Company strengthens its position by appointing Udo Steinhauer.
Thursday, June 06, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!